Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

April 10, 2021April 7, 2021

Posters & Oral Presentations

by Elevation Oncology

Preclinical Diagnostics Genomic Testing Gene Fusions Data Research NRG1 fusion Partnership

Virtual Poster Presentation

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

Save this Presentation

Download PDF

Other Related Resources

October 16, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

September 29, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

October 26, 2020March 1, 2021

Posters & Oral Presentations

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements Read More

January 15, 2021April 7, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

March 29, 2021April 8, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions Read More

April 6, 2021April 6, 2021

Manuscripts

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions Read More